Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 24.64 | 1744.57 | 3544.79 | 4998.26 | 6.25 | 3802.26 | 3807.36 | 5328.47 | 4392.61 | 2884.54 | 3714.74 | 3757.19 | 2325.21 | 3572.92 | 2741.44 | 2819.57 | 144.78 | 313.68 | 559.11 | 258.29 | 221.12 |
| — | -54.1% | -6.9% | -6.2% | -99.9% | +31.8% | +2.5% | +41.8% | +88.9% | -19.3% | +35.5% | +33.3% | +1506.0% | +1039.0% | +390.3% | +991.6% | -34.5% | +822.4% | +2964.9% | -13.8% | — | |
| P/B Ratio | 2.28 | 2.99 | 3.14 | 3.65 | 3.51 | 2.21 | 1.81 | 2.28 | 2.14 | 1.57 | 1.84 | 2.45 | 2.36 | 3.26 | 3.07 | 3.00 | 1.69 | 2.26 | 2.90 | 1.18 | 0.90 |
| — | +35.2% | +73.3% | +59.9% | +64.3% | +41.1% | -1.2% | -6.7% | -9.6% | -51.8% | -40.1% | -18.3% | +39.6% | +43.9% | +5.8% | +154.5% | +88.2% | +51.0% | +190.2% | +118.5% | -56.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 14.2% | -142.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -37344.8% | -1751.0% | -8381.3% | -8115.7% | -10364.5% | -3804.3% |
| — | 0.0% | -85.8% | -242.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +100.3% | +105.7% | +101.2% | +101.2% | -260.3% | +54.0% | -696.1% | -853.1% | +63.2% | — | |
| Operating Margin | -512.9% | -44460.6% | -82389.4% | -92991.7% | -56.7% | -142356.0% | -130369.4% | -121488.9% | -97069.8% | -100259.7% | -77634.7% | -99275.0% | -71144.4% | -82326.4% | -73952.0% | -46729.5% | -2492.5% | -11548.4% | -11985.6% | -13589.3% | -6795.2% |
| — | +68.8% | +36.8% | +23.5% | +99.9% | -42.0% | -67.9% | -22.4% | -36.4% | -21.8% | -5.0% | -112.4% | -2754.4% | -612.9% | -517.0% | -243.9% | +63.3% | -599.4% | -839.3% | +91.9% | — | |
| Net Margin | -483.6% | -44760.2% | -74397.9% | -91178.0% | -49.0% | -134313.3% | -120711.1% | -110729.2% | -89173.3% | -90268.1% | -67419.4% | -92861.1% | -66194.4% | -76476.4% | -69541.8% | -43604.8% | -2418.8% | -11519.9% | -11894.9% | -13526.2% | -6751.4% |
| — | +66.7% | +38.4% | +17.7% | +99.9% | -48.8% | -79.0% | -19.2% | -34.7% | -18.0% | +3.1% | -113.0% | -2636.6% | -563.9% | -484.6% | -222.4% | +64.2% | -599.0% | -835.0% | +92.0% | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.2% | -19.6% | -15.4% | -19.6% | -6.8% | -18.0% | -13.6% | -11.6% | -12.4% | -11.7% | -9.5% | -18.4% | -15.9% | -16.5% | -18.3% | -11.4% | -10.5% | -19.1% | -14.5% | -14.8% | -9.3% |
| — | -8.8% | -13.4% | -69.9% | +45.2% | -53.9% | -43.7% | +37.3% | +22.0% | +29.3% | +48.2% | -61.8% | -51.5% | +13.6% | -26.1% | +22.8% | -13.4% | -9.0% | +11.2% | +88.5% | +64.4% | |
| ROA | -41.7% | -13.5% | -12.4% | -16.3% | -6.0% | -16.2% | -12.4% | -10.5% | -11.3% | -10.7% | -8.7% | -16.3% | -14.0% | -14.9% | -16.6% | -10.5% | -9.5% | -16.7% | -13.3% | -13.6% | -8.3% |
| — | +16.8% | -0.3% | -54.8% | +47.2% | -51.6% | -43.0% | +35.5% | +19.4% | +28.4% | +47.8% | -56.1% | -48.0% | +10.7% | -24.9% | +23.2% | -14.5% | -12.1% | +8.6% | +87.7% | +50.1% | |
| ROIC | -47.3% | -15.2% | -16.3% | -20.1% | -7.7% | -17.2% | -12.8% | -11.7% | -12.9% | -11.3% | -9.6% | -19.4% | -18.0% | -17.7% | -21.2% | -23.4% | -24.1% | -17.6% | -13.8% | -20.6% | -15.4% |
| — | +12.1% | -27.4% | -71.5% | +40.1% | -52.0% | -32.8% | +39.6% | +28.3% | +36.0% | +54.7% | +17.1% | +25.2% | -0.8% | -54.3% | -13.7% | -56.3% | +14.3% | +33.4% | +88.7% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.37 | 0.08 | 0.07 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.07 | 0.02 | 0.02 | 0.01 | 0.01 | 0.04 | 0.00 | 0.00 | 0.00 |
| — | +782.9% | +129.2% | +123.5% | +58.7% | +4.6% | -2.9% | -34.0% | -59.4% | +126.9% | +138.5% | +257.8% | +480.1% | -52.1% | +336.2% | +380.5% | +502.1% | +773.9% | +3.8% | -26.9% | -99.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 12.65 | 16.95 | 15.15 | 12.65 | 11.28 | 11.01 | 19.49 | 15.43 | 18.55 | 15.82 | 23.99 | 18.26 | 13.93 | 12.09 | 12.64 | 12.73 | 17.35 | 7.77 | 12.47 | 14.68 | 15.20 |
| — | +54.0% | -22.3% | -18.0% | -39.2% | -30.4% | -18.8% | -15.5% | +33.2% | +30.9% | +89.9% | +43.5% | -19.7% | +55.6% | +1.3% | -13.3% | +14.1% | +13.2% | +68.6% | +20.9% | +259.3% | |
| Quick Ratio | 12.65 | 16.95 | 15.15 | 12.65 | 11.28 | 11.01 | 19.49 | 15.43 | 18.55 | 15.82 | 23.99 | 18.26 | 13.93 | 12.09 | 12.93 | 12.93 | 17.35 | 7.77 | 12.47 | 14.68 | 15.20 |
| — | +54.0% | -22.3% | -18.0% | -39.2% | -30.4% | -18.8% | -15.5% | +33.2% | +30.9% | +85.5% | +41.3% | -19.7% | +55.6% | +3.7% | -11.9% | +14.1% | +13.2% | +68.6% | +20.9% | +259.3% | |
| Interest Coverage | -68.24 | -14.30 | -29.30 | -17.21 | -60.78 | -194.98 | -147.31 | -91.92 | -75.38 | -107.87 | -81.70 | -71.99 | -85.37 | -330.70 | -412.04 | -292.06 | -181.62 | -191.97 | — | -9693.67 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VRDN stock.
Viridian Therapeutics, Inc.'s current P/E is -5.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Viridian Therapeutics, Inc.'s current operating margin is -512.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Viridian Therapeutics, Inc.'s business trajectory between earnings reports.